• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Behavioral weight-loss program effective in breast cancer survivors

byMonica ParksandDavid Wang
August 21, 2015
in Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a randomized controlled trial of over 600 overweight/obese breast cancer survivors, the use of a group-based, behavioral weight-loss intervention demonstrated significantly increased weight loss compared to standard intervention.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Advancements in the diagnosis and treatment of breast cancer have resulted in a significant increase in the number of breast cancer survivors in the United States, with estimates of up to 2.9 million women. In this population, obesity is associated increased breast cancer-specific and overall mortality in addition to significant cardiovascular and quality-of-life morbidities. However, there has been a paucity of large, randomized studies analyzing the effectiveness of weight-loss intervention among overweight or obese breast cancer survivors. The purpose of this large randomized control trial was to evaluate the effectiveness of a group-based, behavioral weight-loss intervention in this population.

The study randomized over 600 breast cancer survivors who are overweight/obese to either an intensive, group-based weight loss program combined with personal support for 4 months or usual care including counseling on weight loss and physical activity guidelines. At the conclusion of this randomized controlled trial, patients that received intensive, group-based behavioral weight loss intervention demonstrated significantly increased weight loss compared to the control group at 12 months follow-up. This weight loss difference was maintained at two-year follow-up as well. Furthermore, additional measures of cardiovascular health including blood pressure, activity level, and waist circumference also favored the intervention group at 12 months. The results of the study support the use of intensive behavioral weight-loss interventions in obese/overweight breast cancer survivors. However, the study is limited by the relatively-short follow-up period. Furthermore, the study population that was predominantly non-Hispanic white, which may limit the external validity of this study. Additional long-term prospective trials as well as trials focused on minority breast cancer survivors are needed to accurately determine the effectiveness of these weight-loss interventions.

Click to read the study in JCO

Relevant Reading: American Society of Clinical Oncology position statement on obesity and cancer

In-Depth [randomized controlled trial]: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial is a multicenter randomized controlled trial of intense group-based weight loss intervention compared to usual care among overweight/obese breast cancer survivors. The study recruited over 697 breast cancer survivors with a body mass index (BMI) of 25 to 45 across four centers in the United States. Patients were excluded for a history of non-breast malignancy, serious psychiatric illness, and any medical limitation of moderate exercise. Participants were randomized to either an intense, group-based regimen involving 4 months of weekly group sessions with personalized supports (Group 1) or provided usual weight management resources from the public domain, two sessions of individualized diet counseling, and optional seminars on diet and exercise (Group 2). The primary outcome was weight at 12- and 24-months after recruitment. Mean weight loss in group 1 was 6% and 3.7% at 12- and 24-months follow-up, respectively. This was significantly increased compared to 1.5% and 1.1% in the control arm at 12- and 24-months (p<0.05). Systolic and diastolic blood pressures were lower in group 1 at all follow-up visits except for the diastolic blood pressure at 12 months (p<0.05). Waist circumference was reduced in group 1 at 12 months (p=0.004) though not at 24 months. After multivariate analysis, only intervention assignment and age were associated with maintained weight loss at 24 months (p<0.001).

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BMIBreast Cancer
Previous Post

Vemurafenib linked to therapeutic effect in various cancers

Next Post

Increased risk of stroke and coronary heart disease with long work hours

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Next Post
Atrial fibrillation-specific management increases days alive and out of hospital

Increased risk of stroke and coronary heart disease with long work hours

Mesh may be harmful to vaginal structure and function

Mesh may be harmful to vaginal structure and function

Prenatal iron supplementation not linked to placental malaria risk

Prenatal iron supplementation not linked to placental malaria risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options